Ekso Bionics (NASDAQ:EKSO) Stock Crosses Above 50-Day Moving Average – Here’s What Happened

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)’s share price passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $10.61 and traded as high as $11.80. Ekso Bionics shares last traded at $11.95, with a volume of 97,466 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Ekso Bionics in a research note on Friday, March 27th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $6.00.

Ekso Bionics Trading Up 1.3%

The company has a quick ratio of 1.03, a current ratio of 1.55 and a debt-to-equity ratio of 0.25. The company has a fifty day moving average of $10.61 and a two-hundred day moving average of $8.04. The stock has a market capitalization of $42.54 million, a price-to-earnings ratio of -2.22 and a beta of 0.86.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Tuesday, April 28th. The company reported ($2.04) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($2.01). Ekso Bionics had a negative return on equity of 197.81% and a negative net margin of 135.66%.The company had revenue of $2.14 million for the quarter, compared to analyst estimates of $4.29 million. On average, research analysts expect that Ekso Bionics Holdings, Inc. will post -0.1 EPS for the current year.

Insider Buying and Selling at Ekso Bionics

In related news, major shareholder Daniel Asher purchased 15,540 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was purchased at an average cost of $12.30 per share, with a total value of $191,142.00. Following the completion of the acquisition, the insider directly owned 270,432 shares in the company, valued at $3,326,313.60. This trade represents a 6.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 6.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Ekso Bionics

Several institutional investors have recently made changes to their positions in the stock. Roble Belko & Company Inc grew its stake in shares of Ekso Bionics by 104.5% during the 1st quarter. Roble Belko & Company Inc now owns 2,338 shares of the company’s stock worth $25,000 after purchasing an additional 1,195 shares during the period. Virtu Financial LLC purchased a new position in shares of Ekso Bionics in the 3rd quarter valued at about $57,000. Shay Capital LLC purchased a new position in shares of Ekso Bionics in the 3rd quarter valued at about $67,000. Citadel Advisors LLC purchased a new position in shares of Ekso Bionics in the 3rd quarter valued at about $198,000. Finally, Geode Capital Management LLC increased its holdings in shares of Ekso Bionics by 68.9% in the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after purchasing an additional 10,281 shares in the last quarter. 6.42% of the stock is currently owned by hedge funds and other institutional investors.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.